Italia markets closed

Dow Jones
39.862,18
+55,41(+0,14%)
Nasdaq
16.818,46
+23,59(+0,14%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0858
-0,0004(-0,03%)
Bitcoin EUR
63.902,39
-484,38(-0,75%)
CMC Crypto 200
1.503,02
+14,48(+0,97%)

NVCR May 2024 22.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,3500

-0,5200

(-59,77%)

In data: 12:19PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in